Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DA-5219 | Experimental | administered for 2weeks(DA-5219 + StillenĀ® Tab placebo) |
|
| StillenĀ® Tab | Active Comparator | administered for 2weeks(StillenĀ® Tab + DA-5219 placebo) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-5219 | Drug | 1 tablet/day |
| |
| StillenĀ® Tab |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement rate of gastric mucosal erosion | Change from baseline at 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Cure rate for gastric mucosal erosion | Change from baseline at 2 weeks | |
| Cure rate for gastric mucosal edema | Change from baseline at 2 weeks | |
| Improvement rate for gastric mucosal erythema |
Not provided
Main Inclusion Criteria:
Main Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asan Medical Center | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C116959 | DA 9601 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
3 tablets/day |
|
| DA-5219 Placebo | Drug | 1 tablet/day |
|
| StillenĀ® Tab Placebo | Drug | 3 tablets/day |
|
| Change from baseline at 2 weeks |
| Improvement rate for gastric mucosal bleeding | Change from baseline at 2 weeks |
| Improvement rate for gastric subjective symptoms | Change from baseline at 2 weeks |